Status:
UNKNOWN
Puerarin Versus Atorvastatin in Treating Metabolism Syndrome in Patients With Chronic Rheumatic Diseases
Lead Sponsor:
Chengdu PLA General Hospital
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
To evaluate the Effect of Puerarin tablets versus statins in treating metabolism syndrome in patients with chronic rheumatic diseases
Eligibility Criteria
Inclusion
- patients with a definite diagnose with rheumatic disease
- patients with metabolic Syndrome
- without conflict to the written, informed consent signed prior to the enrollment
- no severe hepatic or renal disorders
- no known carotid artery stenosis
- no coagulation disorders
- no hypertension
Exclusion
- being in pregnancy, lactation period or under a pregnancy plan
- being allergic to the test drug
- not compatible for the trial medication
- without full legal capacity
Key Trial Info
Start Date :
August 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2018
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT02219191
Start Date
August 1 2014
End Date
December 1 2018
Last Update
April 4 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
270 Rongdu street, Jin-niu district,Rheumatology Center of Integrated Medicine, General Hospital of Chengdu Military Area Command PLA，
Chengdu, Sichuan, China, 610083